PER 0.00% 10.0¢ percheron therapeutics limited

News: ANP Antisense Therapeutics says ATL1102 for MS Phase IIb IND submitted to FDA for review, page-8

  1. 11,041 Posts.
    lightbulb Created with Sketch. 985
    I agree.
    All we can do in the interim is hope, wait and see.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.